DE3146841A1 - Wound-treatment compositions - Google Patents
Wound-treatment compositionsInfo
- Publication number
- DE3146841A1 DE3146841A1 DE19813146841 DE3146841A DE3146841A1 DE 3146841 A1 DE3146841 A1 DE 3146841A1 DE 19813146841 DE19813146841 DE 19813146841 DE 3146841 A DE3146841 A DE 3146841A DE 3146841 A1 DE3146841 A1 DE 3146841A1
- Authority
- DE
- Germany
- Prior art keywords
- gelatin
- wound treatment
- wound
- treatment agent
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0038—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
Neues Wundbehand lungsmittel. New wound treatment agent.
Die Erfindung betrifft ein Wundbehandlungsmittel, seine Verwendung sowie ein Verfahren zu seiner Herstellung. The invention relates to a wound treatment agent and its use and a method for its production.
Es ist bekannt, daß man die Wundheilung bei schwer heilenden Wunden, wie Ulcera, diabetischem Gangräen, Verbrennungen oder infizierten Wunden unterstützen kann, indem man die Wunden mit trocknenden, dh. aufsaugenden, reinigenden und das Bakterienwachstum verhindernden Mitteln versorgt Verschiedenartige Wundbehandlungsmittel wurden bisher vorgeschlagen. It is known that wound healing in wounds that are difficult to heal, such as ulcers, diabetic gangrene, burns or infected wounds can by treating the wounds with drying, ie. absorbent, cleansing and that Bacterial Growth Preventive Agents supplies various wound treatment agents have been proposed so far.
Zumeist handelt es sich dabei um Polyzucker-Verbindungen, wie Dextranomere, wie beispielsweise in der US-PS 4 225 580 beschrieben. Daneben sind auch bereits vernetzte Stärke vorgeschlagen worden, vgl. DE-OS 2 908 437, sowie Polyvinylalkohol, vgl. EP-OS 22 064. Für die praktische Anwendung haben sich diese Mittel jedoch nicht in allen Fäilen als zufriedenstellend erwiesen. So erleiden die genannten, bekannten Hydrogele im Gewebe kaum oder nur einen extrem langsamen Abbau und es ist daher für eine gute Wundheilung erforderlich, solche Wundbehandlungsmittel wieder vollständig von der Wunde zu entfernen. Ebenso ist der günstige Effekt auf die Wundheilung selbst in vielen Fällen verbesserungswürdig.Mostly these are polysugar compounds, such as dextranomers, as described, for example, in U.S. Patent 4,225,580. Besides that are also already cross-linked starch has been proposed, see DE-OS 2 908 437, and polyvinyl alcohol, see EP-OS 22 064. However, these means have not been used in practice proved satisfactory in all cases. This is how the well-known people named suffer Hydrogels in the tissue hardly or extremely slow degradation and it is therefore For good wound healing, such wound treatment agents are required to be completely restored remove from the wound. Likewise, it has a beneficial effect on wound healing itself in many cases could be improved.
Aufgabe der Erfindung war es, ein Wundheilungsmittel zu schaffen, das die aufgezeigten Nachteile nicht, oder nicht in dem bekannten Maße aufweist. The object of the invention was to create a wound healing agent, which does not have the disadvantages indicated, or does not have the known extent.
Demgemäß betrifft die Erfindung ein Wundbehandlungsmittel, enthaltend quervernetzte Gelatine. Accordingly, the invention relates to a wound treatment agent containing cross-linked gelatin.
Wenn man Gelatine, beispielsweise in fester Form, als Pulver, Schuppen oder Granulat einer Vernetzung unterzieht, erhält man Produkte, die nicht mehr wasserlöslich sind, dafür aber die Eigenschaften mechanisch stabiler Gele besitzen, die je nach Vernetzungsgrad das 3 bis 8fache ihres Eigengewichts an Wasser absorbieren können. Die so erhaltene, quervernetzte Gelatine, insbesondere in Form von Pulver, Schuppen oder Granulat, ist aufgrund ihres hohen Wasser- und Sekretaufnahmevermögens in überraschend guter Weise geeignet, Wunden zu reinigen und zu trocknen, so daß eine verstärkte Wundgranulation und damit Heilung einsetzen kann. Dabei wird die erfindungsgemäß verwendete quervernetzte Gelatine je nach Vernetzungsgrad mehr oder weniger schnell vom Gewebe resorbiert, da die Grundstrukturen der Eiweißketten erhalten sind, so daß bei nicht vollständigem Auswaschen des Granulats verbleibende Reste im Gewebe abgebaut und resorbiert werden. If you have gelatin, for example in solid form, as a powder, flakes or granules are crosslinked, products are obtained that are no longer water-soluble are, but have the properties of mechanically stable gels, which depending on Degree of crosslinking can absorb 3 to 8 times their own weight in water. The cross-linked gelatin obtained in this way, especially in the form of powder, flakes or granules, is surprising due to their high water and secretion absorption capacity well suited to cleansing and drying wounds, so that a reinforced Wound granulation and thus healing can begin. In doing so, according to the invention used cross-linked gelatin more or less quickly depending on the degree of cross-linking absorbed by the tissue, since the basic structures of the protein chains are preserved, so that if the granulate is not completely washed out, residues remain in the tissue be broken down and reabsorbed.
Die erfindungsgemäß verwendete quervernetzte Gelatine wird in an sich bekannter Weise insbesondere durch Umsetzung von Gelatine mit Vernetzungsreagenzien, wie Formaldehyd, Glyoxal, Glutardialdehyd, Dicarbonsäurechloriden undioder Diisocyanaten erhalten. Dabei kann man vorteilhaft so vorgehen, daß man Gelatine in Form von Blättchen, Schuppen, Pulver oder Granulat in Eiswasser vorlegt und ohne vorherige Auflösung der Gelatine die Vernetzung durchführt. Besonders bevorzugt ist eine Vernetzung mit einem Diisocyanat, wie Hexamethylendiisocyanat. The crosslinked gelatin used according to the invention is in an known way, in particular by reacting gelatin with crosslinking reagents, such as formaldehyde, glyoxal, glutaraldehyde, dicarboxylic acid chlorides and / or diisocyanates obtain. It can be advantageous to proceed in such a way that gelatin in the form of flakes, Put flakes, powder or granules in ice water and do not dissolve beforehand the gelatin carries out the crosslinking. Crosslinking is particularly preferred with a diisocyanate such as hexamethylene diisocyanate.
Die erfindungsgemäße Verwendung der quervernetzten Gelatine in Wundbehandlungsmitteln kann insbesondere so erfolgen, daß man die Wunde mit dem Mittel in Pulverform bestreut, ohne daß die Wunde berührt wird. Anschließend wird mit einem leichten Verband gesichert. Aufgrund des hohen Saugvermögens des Wundbehandlungsmittels wird das mit Bakterien und nekrotischem Gewebe belastete Wundsekret vom Wundgrund weg in die Gelpartikel transportiert. so daß ein sauberer Wundgrund zurückbleibt. The use according to the invention of the crosslinked gelatin in wound treatment agents can in particular be carried out in such a way that the wound is sprinkled with the agent in powder form, without touching the wound. Then it is secured with a light bandage. Due to the high absorbency of the wound treatment agent, this becomes with bacteria and necrotic tissue loaded wound exudate away from the wound bed into the gel particles transported. so that a clean wound bed remains.
Dabei kann es vorteilhaft sein, dem erfindungsgemäßen Wundbehandlungsmittel weitere übliche Zusatzstoffe zuzusetzen, vor oder auch nach Vernetzung, beispielsweise Desinfektionsmittel und/oder Antibiotika.It can be advantageous to use the wound treatment agent according to the invention to add further customary additives, before or after crosslinking, for example Disinfectants and / or antibiotics.
Ein Verbandwechsel bzw. der Austausch der vollgesogenen Gelpartikel erfolgt vorteilhaft durch Aussprühen der Wunde mit physiologischer Kochsalziösung. Bei der Behandlung stark kontaminierter Wunden ist der Zusatz antimikrobiell wirkender Substanzen zum Granulat oder dergleichen besonders zweckmäßig. A dressing change or the exchange of the soaked gel particles is advantageously carried out by spraying the wound with physiological saline solution. When treating heavily contaminated wounds, the addition is more antimicrobial Substances for granules or the like are particularly useful.
Die folgenden Beispiele erläutern die Erfindung, wobei der Fachmann aufgrund seines Wissens Abwandlungen vornehmen kann, ohne die Erfindung zu verlassen. The following examples explain the invention to those skilled in the art can make modifications based on his knowledge without departing from the invention.
Beispiel 1 Gelatine gepulvert (10 g) wird in eine Mischung aus 100 g Eis und 100 g Wasser eingetragen und unter Rühren mit 0,5 g Hexamethylendiisocyanat vernetzt. Man läßt 3 Stunden bei Raumtemperatur reagieren und danach weitere 3 Stunden bei 400C. Die vernetzten Gelatinepartikei werden mit Isopropanol gewaschen und dann bei 50"C getrocknet. Man erhält ein weißgelbliches Pulver mit einem Wasseraufnahmevermögen von 7-8g/g, das sowohl in kaltem als auch heißem Wasser quillt aber uniöslich ist. Example 1 Powdered gelatin (10 g) is added to a mixture of 100 Added g of ice and 100 g of water and, with stirring, with 0.5 g of hexamethylene diisocyanate networked. The reaction is allowed to take place for 3 hours at room temperature and then for a further 3 hours at 400C. The crosslinked gelatin particles are washed with isopropanol and then dried at 50 ° C. A yellowish-white powder with a water absorption capacity is obtained of 7-8g / g, which swells in both cold and hot water but is insoluble.
Beispiel 2 15 g Blattgelatine werden in 400 g Eiswasser mit 1,0 g Hexamethylen diisocyanat 2 Stunden und dann weitere 3 Stunden bei Raumtemperatur gerührt. Die Lösung wird abgesaugt, der Rückstand mit Isopropanol gewaschen und bei 50"C getrocknet Man erhält Gelatineplättchen mit einem Wasseraufnahmevermögen von 6 - 7 g. Example 2 15 g of gelatine leaves are added to 400 g of ice water with 1.0 g Hexamethylene diisocyanate 2 hours and then a further 3 hours at room temperature touched. The solution is filtered off with suction, the residue is washed with isopropanol and dried at 50 ° C. This gives gelatin platelets with a water absorption capacity from 6 - 7 g.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19813146841 DE3146841A1 (en) | 1981-11-26 | 1981-11-26 | Wound-treatment compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19813146841 DE3146841A1 (en) | 1981-11-26 | 1981-11-26 | Wound-treatment compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3146841A1 true DE3146841A1 (en) | 1983-06-01 |
Family
ID=6147234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19813146841 Withdrawn DE3146841A1 (en) | 1981-11-26 | 1981-11-26 | Wound-treatment compositions |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE3146841A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0365705A1 (en) * | 1988-10-26 | 1990-05-02 | Zentralna Problemna Laboratoria Po Kryobiologia I Lyophilisazia | Biopreparation for the treatment of wounds |
WO1992013578A1 (en) * | 1990-07-09 | 1992-08-20 | Bausch & Lomb Incorporated | A biologically derived medical adhesive and its uses |
WO1997041899A1 (en) * | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
WO1998055161A1 (en) * | 1997-06-03 | 1998-12-10 | Innogenetics N.V. | New medicaments based on polymers composed of methacrylamide-modified gelatin |
WO2005009448A1 (en) * | 2003-07-24 | 2005-02-03 | Ooo Delsi | Treatment of lesions of the soft tissues |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
US7923031B2 (en) | 2004-01-30 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic sprays and compositions |
US7955288B2 (en) | 2002-12-11 | 2011-06-07 | Ferrosan Medical Devices A/S | Gelatine-based materials as swabs |
US8021684B2 (en) | 2004-07-09 | 2011-09-20 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
US8642831B2 (en) | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
-
1981
- 1981-11-26 DE DE19813146841 patent/DE3146841A1/en not_active Withdrawn
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0365705A1 (en) * | 1988-10-26 | 1990-05-02 | Zentralna Problemna Laboratoria Po Kryobiologia I Lyophilisazia | Biopreparation for the treatment of wounds |
WO1992013578A1 (en) * | 1990-07-09 | 1992-08-20 | Bausch & Lomb Incorporated | A biologically derived medical adhesive and its uses |
WO1997041899A1 (en) * | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
WO1998055161A1 (en) * | 1997-06-03 | 1998-12-10 | Innogenetics N.V. | New medicaments based on polymers composed of methacrylamide-modified gelatin |
US6458386B1 (en) | 1997-06-03 | 2002-10-01 | Innogenetics N.V. | Medicaments based on polymers composed of methacrylamide-modified gelatin |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
US8283320B2 (en) | 2001-12-21 | 2012-10-09 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostasis |
US7955288B2 (en) | 2002-12-11 | 2011-06-07 | Ferrosan Medical Devices A/S | Gelatine-based materials as swabs |
WO2005009448A1 (en) * | 2003-07-24 | 2005-02-03 | Ooo Delsi | Treatment of lesions of the soft tissues |
JP2006528622A (en) * | 2003-07-24 | 2006-12-21 | オーオーオー デルシ | Treatment of soft tissue damage |
US7923031B2 (en) | 2004-01-30 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic sprays and compositions |
US8021684B2 (en) | 2004-07-09 | 2011-09-20 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
US8642831B2 (en) | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US9533069B2 (en) | 2008-02-29 | 2017-01-03 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10799611B2 (en) | 2012-06-12 | 2020-10-13 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10595837B2 (en) | 2013-06-21 | 2020-03-24 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11103616B2 (en) | 2013-12-11 | 2021-08-31 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3146841A1 (en) | Wound-treatment compositions | |
AT393795B (en) | COHERENT, POROESIC COLLAGEN FILM MATERIAL AND METHOD FOR THE PRODUCTION THEREOF | |
EP0048323B1 (en) | Product in powder form for the treatment of wounds, and method for the preparation thereof | |
DE4026153C2 (en) | ||
DE3608158C2 (en) | ||
DE3444746A1 (en) | PROTEOLYTIC Wound Bandage And Its Manufacture | |
DE69817574T2 (en) | MANUFACTURING METHOD FOR A FIBER-FREE, POROUS MATERIAL | |
DE3203957C2 (en) | ||
EP0075791A1 (en) | Absorbent wound dressing and processes for its production | |
DE3429038A1 (en) | ACTIVE SUBSTANCE DEPOT | |
CH646607A5 (en) | HAEMOSTATIC AGENT AND METHOD FOR THE PRODUCTION THEREOF. | |
EP0209726A2 (en) | Soluble collagen sponge | |
DD145062A5 (en) | TRANSPARENT LIQUID ASSOCIATED MATERIAL | |
DE69925757T2 (en) | DEXTRAN MALEIC ACID MONOESTER AND HYDROGELES THEREOF | |
DE102009036995B4 (en) | Collagen-based matrix for use as a restorative material and method of making the same | |
DE2635508A1 (en) | ANTISEPTIC BODY | |
DE112013006917T5 (en) | Carboxymethylcellulose foam for hemostatic treatment and wound treatment and method of making the same | |
DE212012000057U1 (en) | Antimicrobial blend and antimicrobial coverage to aid wound healing | |
DE2849570A1 (en) | TRANSPARENT LIQUID ASSOCIATION MATERIAL | |
CH615099A5 (en) | ||
DE2823620A1 (en) | COLLAGEN SKIN DRESSING MATERIAL | |
DE2908437A1 (en) | NETWORKED HYDROXYAETHYL STARCH | |
DE2209499B2 (en) | Flat substrate with a collagen coating | |
DE3826419A1 (en) | Wound healing promoting medicinal product and process for its manufacture | |
DE3334595A1 (en) | ACTIVE SUBSTANCE DEPOSIT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |